



CASE 4-20921/A

Docket Number		4-20921/A
FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10		
EL138342775US Express Mail Label Number		March 12, 2001 Date of Deposit

#14
AKD
3.22.01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1615

WAGNER ET AL.

Examiner: Di Nola Baron, L.

APPLICATION NO: 09/202,805

FILED: MAY 7, 1999

FOR: SOLID ORAL DOSAGE FORMS OF VALSARTAN

Assistant Commissioner for Patents
Washington, D.C. 20231


SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c).
A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.



The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6807



Diane Tso
Attorney for Applicants
Reg. No. 46,012

Date: March 12, 2001